Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
Chronic CED of TPT for Recurrent Malignant Glioma
- Conditions
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Jeffrey N. Bruce
- Target Recruit Count
- 6
- Registration Number
- NCT06666712
- Locations
- 🇺🇸
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionOther: Patient ObservationProcedure: Computed TomographyProcedure: Bone ScanDrug: CyclophosphamideBiological: DactinomycinProcedure: ResectionProcedure: Ultrasound ImagingDrug: DexrazoxaneDrug: VincristineDrug: DoxorubicinProcedure: EchocardiographyDrug: IfosfamideProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyDrug: Topotecan
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 110
- Registration Number
- NCT06647953
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Genmab
- Target Recruit Count
- 530
- Registration Number
- NCT06619236
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 404
- Registration Number
- NCT06616532
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, China
🇨🇳Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
🇨🇳The First Affiliated Hospital Of Ningbo University, Ningbo, Zhejiang, China
A Study of GSK5764227 in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT06551142
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Oral Topotecan With Toripalimab for Patients With Endometrial Cancer
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06548763
- Locations
- 🇨🇳
Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06528496
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 652
- Registration Number
- NCT06500026
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 460
- Registration Number
- NCT06498479
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06496048
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.